FDA Approvals in Oncology: April-June 2026
During the second quarter of 2026, oncology approvals issued by the U.S. Food and Drug Administration expanded the treatment...
Category: Policy
During the second quarter of 2026, oncology approvals issued by the U.S. Food and Drug Administration expanded the treatment...
At the AACR Annual Meeting 2026, National Cancer Institute Director Anthony Letai offered insights into what NCI considers to...
Heather K. Beasley was among the researchers who visited Washington, D.C to push for sustained NIH funding during AACR...
In the first quarter of 2026, the FDA issued nine approvals in oncology, including treatments for blood cancers, pancreatic...
In the last quarter of 2025, the FDA announced 20 approvals in oncology, including treatments for lung cancer, multiple...
The FDA is proposing a cap on nicotine in cigarettes that would reduce the amount by 95%, which could...
A series published in the AACR journal Clinical Cancer Research shared key considerations for improving dosage optimization in oncology.
From July 1 to September 30, 2025, the FDA issued eight new oncology approvals, expanding treatment options for patients...
Richard and Michelle Schlueter attended the Rally for Medical Research to advocate for NIH funding after budget cuts delayed...
A workshop hosted by AACR and FDA explored novel clinical trial oncology endpoints and considerations for their validation and...